Article Abstract

Emerging new predictive biomarkers in metastatic breast cancer: Caveolin-1 and weekly nab-paclitaxel plus gemcitabine, are we on for tomorrow?

Authors: Francesco Ricci, Christophe Le Tourneau


Despite the considerable progresses and the high efficacy of adjuvant medical treatments (chemotherapy, hormonotherapy and targeted therapy) in early breast cancer, up to a third of breast cancer patients still recur and die (1). As breast cancer comprehends a large spectrum of different tumor phenotypes, some with a more indolent behavior and others, more aggressive, with a poor short-term outcome, a major clinical issue has arisen as how to handle patients with metastatic disease.